Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2011-05-31
2011-05-31
Lucas, Zachariah (Department: 1648)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C536S023100
Reexamination Certificate
active
07951786
ABSTRACT:
The present disclosure relates to oligodeoxynucleotides that suppress an immune response. Methods are disclosed for preventing or treating inflammatory arthropathies by administering a therapeutically effective amount of a suppressive oligodeoxynucleotide.
REFERENCES:
patent: 4469863 (1984-09-01), Ts'o et al.
patent: 5023243 (1991-06-01), Tullis
patent: 5663153 (1997-09-01), Hutcherson et al.
patent: 6214806 (2001-04-01), Krieg et al.
patent: 7094766 (2006-08-01), Gilchrest et al.
patent: 7514414 (2009-04-01), Klinman et al.
patent: 7514415 (2009-04-01), Klinman et al.
patent: 2003/0087848 (2003-05-01), Bratzler et al.
patent: 2004/0132682 (2004-07-01), Klinman et al.
patent: 2004/0248834 (2004-12-01), Klinman et al.
patent: 2006/0074039 (2006-04-01), Klinman et al.
patent: 2009/0208468 (2009-08-01), Klinman et al.
patent: 0 092 574 (1992-04-01), None
patent: 1 167 377 (2002-01-01), None
patent: WO 83/01451 (1983-04-01), None
patent: WO 95/26204 (1995-09-01), None
patent: WO 96/02555 (1996-02-01), None
patent: WO 98/11211 (1998-03-01), None
patent: WO 98/18810 (1998-05-01), None
patent: WO 98/37919 (1998-09-01), None
patent: WO 98/40100 (1998-09-01), None
patent: WO 98/52581 (1998-11-01), None
patent: WO 99/51259 (1999-10-01), None
patent: WO 03/027313 (2003-04-01), None
Schnitzer and Hochberg. COX-2-selective inhibitors in the treatment of arthritis. Cleveland Clinic Journal of Medicine. Apr. 2002. vol. 69, Supplement 1. p. SI-20-30.
Burt et al. Treatment of autoimmune disease by intense immunosuppressive conditioning and autologous hematopoietic stem cell transplantation. Blood. Nov. 15, 1998;92(10):3505-14.
McCluskie et al. Parenteral and mucosal prime-boost immunization strategies in mice with hepatitis B surface antigen and CpG DNA. 2002. FEMS Immunology and Medical Microbiology. 32: 179-185.
Battegay, “Angiogenesis: mechanistic insignts, neovascular diseases, and therapeutic prospects,”J. Molec. Med. 73(7): 333-346, (1995).
Beck et al., “Vascular development: cellular and molecular regulation,”FASEB J. 11(5): 365, (1997).
Bjersing et al., “Anti-proliferative effects of phosphodiester oligodeoxynucleotides,”Immunobiology, 209(8):637-45, (2004).
Braun et al., “On the Difficulties of Establishing a Consensus on the Definition of and Diagnostic Investigations for Reactive Arthritis,”J. Rheumatol. 27:2185-2192, (2000).
Britigan et al., “Lactoferrin Binds CpG-Containing Oligonucleotides and Inhibits Their Immunostimulatory Effects on Human B Cells,”J. Immunol. 167:2921-2928, (2001).
Chen et al., “Identification of methylated CpG motifs as inhibitors of the immune stimulatory CpG motifs,”Gene Ther. 8(13):1024-1032, (2001).
Deng et al., “Intra-articularly localized bacterial DNA containing CpG motifs induces arthritis,”Nat. Med. 5:702-705, (1999).
Deng et al., “Synovial cytokine mRNA expression during arthritis triggered by CpG motifs of bacterial DNA,”Arthritis Res. 3(1):48-53, 2001.
Deng et al., “The Features of Arthritis Induced by CpG Motifs in Bacterial DNA,”Arthritis Rheum. 43:356-364, (2000).
Dong et al., “Suppressive Oligodeoxynucleotides Delay the Onset of Glomerulonephritis and Prolong Survival in Lupus-Prone NZB X NZW Mice,”Arthritis&Rheumatism52(2):651-658 (Feb. 2005).
Dong et al., “Suppressive Oligonucleotides Protect Against Collagen-Induced Arthritis in Mice,”Arthritis&Rheumatism50(5):1686-1689 (May 2004).
Enokizono et al., “Structure of hnRNP D Complexed with Single-stranded Telomere DNA and Unfolding of the Quadruplex by Heterogeneous Nuclear Ribonucleoprotein D,”J. Biological Chemistry280(19):18862-18870 (2005).
Gaudric et al. “Quantification of Angiogenesis due to Basic Fibroblast Growth Factor in a Modified Rabbit Corneal Model,”Ophthal. Res. 24: 181, (1992).
Gürsel et al., “Differential and competitive activiation of human immune cells by distinct classes of CpG oligodeoxynucleotide,”J. Leuko.Biol. 71:813-820, (2002).
Gursel et al., “Repetitive Elements in Mammalian Telomeres Suppress Bacterial DNA-Induced Immune Activation,”J. Immunology171:1393-1400 (2003).
Gursel et al., “Sterically Stabilized Cationic Liposomes Improve the Uptake and Immunostimulatory Activity of CpG Oligonucleotides,”J. Immunol. 167: 3324, (2001).
Han et al., “G-quadruplex DNA: a potential target for anti-cancer drug design,”Trends Pharmacol. Sci. 21:136-142, (2000).
Hartmann et al., “CpG DNA: A potent signal for growth, activation, and maturation of human dendritic cells,”Proc. Natl. Acad. Sci. USA96:9305-9310, (1999).
Ho et al., “An Immunomodulatory GpG Oligonucleotide for the Treatment of Autoimmunity via the Innate and Adaptive Immune Systems,”J. Immunol. 171:4920-4926, (2003).
International Search Report from the prior PCT Application No. PCT Application No. PCT/US2003/024205, 3 pages, (mailed on Nov. 18, 2005).
Iwakura et al., “The Development of Autoimmune Inflammatory Arthropathy in Mice Transgenic for the Human T Cell Leukemia Virus Type-1 env-pX Region is not Dependent on H-2 Haplotypes and Modified by the Expression Levels of Fas Antigen,”J. Immunology161:6592-6598, (1998).
Kenyon et al., “A Model of Angiogenesis in the Mouse Cornea,”Invest Opthalmol. Vis. Sci. 37:1625-1632, (1996).
Klinman et al., “Activation of the innate immune system by CpG oligodeoxynucleotides: immunoprotective activity and safety,”Springer Semin. Immunopathol. 22:173-183, (2000).
Klinman et al., “Contribution of CpG Motifs to the Immunogenicity of DNA Vaccines,”J.Immunol. 158:3635-3639, (1997).
Klinman et al., “CpG Motifs present in bacterial DNA rapdily induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon γ,”Proc. Natl. Acad. Sci. USA 93:2879, (1996).
Krieg et al., “CpG motifs in bacterial DNA trigger direct B-cell activation,”Nature374:546-549, (1995).
Krieg et al., “Enhancing vaccines with immune stimulatory CpG DNA,”Curr Opin Mol Ther3(1):15-24, (2001).
Krieg et al., “Sequence motifs in adenoviral DNA block immune activation by stimulatory CpG motifs”Proc. Natl. Acad. Sci. USA95:12631-12636, (1998).
Krieg, “Commentary: A possible cause of joint destruction in septic arthritis,”Arthritis Research1(1):3-4, (1999).
Krieg, “CpG Motifs in bacterial DNA and their immune effects,”Annu Rev Immunol20:709-760, (2002).
Krieg, “From A to Z on CpG,”Trends Immunol. 23(2):64-65, (2002).
Krieg, “From bugs to drugs: therapeutic immunomodulation with oligodeoxynucleotides containing CpG sequences from bacterial DNA,”Antisense Nucleic Acid Drug Dev11(3):181-188; (2001).
Lenert et al., “CpG stimulation of primary mouse B cells is blocked by inhibitory oligodeoxyribonuceotides at a site proximal to NF-kappaB activation.”Antisense Nucleic Acid Drug Dev11(4):247-256, (2001).
Liang et al., “Activation of Human B Cells by Phosphorothioate Oligodeoxynucleotides,”J. Clin. Invest. 98:1119-1129, (1996).
Lichtenberg et al., “The Rat Subcutaneous Air Sac Model: A Quantitative Assay of Antiangiogenesis in Induced Vessels,”Pharmacol Toxicol. 84:34-40, (1999).
Matsukawa et al.,Clin. Exp. Immunol., 93:206-211.
Murchie et al., “Tetraplex folding of telomere sequences and the inclusion of adenine bases,”EMBO J. 13:993-1001, (1994).
Pisetsky et al., “Immunological Properties of Bacterial DNA,”NY Acad Sci. 772:152-163, (1995).
Pisetsky et al., “Inhibition of Murine Macrophage IL-12 Production by Natural and Synthetic DNA,”Clin. Immunol. 96, 198-204, (2000).
Quarcoo et al., “Inhibition of signal transducer and activator of transcription 1 attenuates allergen-induced airway inflammation and hyperreactivity,”J Allergy Clin Immunol., 114(2):288-95, (2004).
Roman et al.,
Gursel Ihsan
Gursel Mayda
Klinman Dennis
Verthelyi Daniela
Zeuner Rainald
Horning Michelle
Klarquist & Sparkman, LLP
Lucas Zachariah
The United States of America as represented by the Department of
LandOfFree
Method of treating inflammatory arthropathies with... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treating inflammatory arthropathies with..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treating inflammatory arthropathies with... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2680677